Araki Kazuhiro

アラキカズヒロ | Araki Kazuhiro

Affiliation and department：
Job title：化学療法部長(通院治療センター長)

Research field (1)： Tumor diagnostics and therapeutics

Research theme for competitive and other funds (12)：

2019 - 2022 Application for liquid biomarker as a medical communication tool in oncology practice
2016 - 2020 research of ideal strategy for predictive factor related with genetic alteration resistance of cancer chemotherapy in metastatic advanced breast cancer
2008 - 2009 末梢神経障害を生じうる化学療法とのガバペンチン併用投与の安全性確認試験
2008 - タモキシフェンの薬剤応答に関連した薬理遺伝学的・臨床薬理学的研究
2008 - レトロゾールの薬剤応答に関連した薬理遺伝学的・臨床薬理学的研究

Show all

Papers (2)：

Yuichiro Kikawa, Yasuhiro Hagiwara, Tomomi Fujisawa, Kazuhiro Araki, Takayuki Iwamoto, Takafumi Sangai, Tadahiko Shien, Shintaro Takao, Reiki Nishimura, Masato Takahashi, et al. Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy. PloS one. 2022. 17. 11. e0278344
Kazuhiro Araki, Yasuo Miyoshi. Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer. Translational Cancer Research. 2018. 7. S514-S518

MISC (208)：

Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, Kazuhiro Araki, Yoshinori Ito, Toshimi Takano, Masato Takahashi, Junji Tsurutani, Kei Koizumi, Masahiro Kitada, et al. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) (vol 21, 391, 2020). TRIALS. 2020. 21. 1
Takayuki Iwamoto, Tomomi Fujisawa, Tadahiko Shien, Kazuhiro Araki, Kentaro Sakamaki, Takafumi Sangai, Yuichiro Kikawa, Shintaro Takao, Reiki Nishimura, Masato Takahashi, et al. The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs. Breast cancer (Tokyo, Japan). 2020. 27. 5. 973-981
Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, Kazuhiro Araki, Yoshinori Ito, Toshimi Takano, Masato Takahashi, Junji Tsurutani, Kei Koizumi, Masahiro Kitada, et al. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). Trials. 2020. 21. 1. 391-391
Yuichiro Kikawa, Kentaro Sakamaki, Tomomi Fujisawa, Kazuhiro Araki, Takayuki Iwamoto, Takafumi Sangai, Tadahiko Shien, Shintaro Takao, Reiki Nishimura, Masato Takahashi, et al. HEALTH-RELATED QUALITY OF LIFE IN 2ND-LINE ENDOCRINE THERAPY FOR PATIENTS WITH ACQUIRED ENDOCRINE-RESISTANT POSTMENOPAUSAL ER-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER: THE HORSE-BC STUDY. BREAST. 2019. 48. S72-S73
藤澤知巳, 宮本武志, 矢内恵子, 荒木和浩, 柳田康弘. 乳癌術前化学療法の臨床的奏功と予後についての考察. 日本癌治療学会学術集会抄録集. 2019. 57回. P56-7

ｍore...

Lectures and oral presentations (1)：

Lapatinib Resistance Confers Cross-Resistance to Microtubule Inhibitors in ErbB2-Overexpressing Breast Cancer Cells.
(The 2010 CTRC-AACR San Antonio Breast Cancer Symposium 2010)

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page